Viking Therapeutics Aktie

28,49 EUR +0,31 EUR +1,08 %

22:13:50

BMN

28,26 EUR -0,25 EUR -0,88 %

22:07:39

HAML

Viking Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.2,98 Mrd. EUR

Div. Rendite0,00%

WKNA12GD6

ISINUS92686J1060

SymbolVKTX

Viking Therapeutics Aktien News

Sortieren:Datum Meistgelesen

19.11.24PR NewswireViking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

19.11.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

12.11.24PR NewswireViking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

04.11.24PR NewswireViking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024

31.10.24PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences

28.10.24PR NewswireViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

23.10.24PR NewswireViking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

16.10.24PR NewswireViking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024

09.10.24PR NewswireViking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

28.08.24PR NewswireViking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference

24.07.24PR NewswireViking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

17.07.24PR NewswireViking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024

24.06.24PR NewswireViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association

04.06.24PR NewswireViking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

30.05.24PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences

24.04.24PR NewswireViking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

17.04.24PR NewswireViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

26.03.24PR NewswireViking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

27.02.24PR NewswireViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

07.02.24PR NewswireViking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

31.01.24PR NewswireViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024

13.11.23PR NewswireViking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

02.11.23PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences

25.10.23PR NewswireViking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

23.10.23PR NewswireViking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

18.10.23PR NewswireViking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023

17.10.23PR NewswireViking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

10.10.23PR NewswireViking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

07.09.23PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences

06.09.23PR NewswireViking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

26.07.23PR NewswireViking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

19.07.23PR NewswireViking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023

16.05.23PR NewswireViking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

26.04.23PR NewswireViking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

20.04.23PR NewswireViking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023

11.04.23PR NewswireViking Therapeutics to Present at 22nd Annual Needham Healthcare Conference

Viking Therapeutics News

Viking Therapeutics News: auf dieser Seite finden Sie alle Viking Therapeutics News und Nachrichten zur Viking Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Viking Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Viking Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.